We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Bioanalysis
BioTechniques
Future Drug Discovery
Future Medicinal Chemistry
Future Science OA
International Journal of Pharmacokinetics
Pharmaceutical Patent Analyst
Therapeutic Delivery
Special ReportOpen Accesscc iconby icon

Catabolic and anabolic faces of insulin resistance and their disorders: a new insight into circadian control of metabolic disorders leading to diabetes

    Polina M Schwartsburd

    *Author for correspondence:

    E-mail Address: P.Schwartsburd@rambler.ru

    Institute of Theoretical & Experimental Biophysics, Russian Academy of Sciences, Pushchino, Moscow Region, 142290, Russia

    Search for more papers by this author

    Published Online:26 Jun 2017https://doi.org/10.4155/fsoa-2017-0015

    Abstract

    Maintenance of glucose homeostasis during circadian behavioral cycles is critical. The processes controlling the switch between predominant lipolysis/fatty oxidation during fasting and predominant lipid storage/glucose oxidation following feeding are determined principally by insulin. Chronic elevated threshold of insulin resistance (IR) is a key pathological feature of obesity, Type 2 diabetes, sepsis and cancer cachexia; however, a temporal reduced threshold of IR is widely met in fasting/hibernation, pregnancy, antibacterial immunity, exercise and stress. Paradoxically, some of these cases are associated with catabolic metabolism, whereas others are related to anabolic pathways. This article considers the possible causes of circadian disorders in glucose and lipid metabolism that act as a driving force for obesity-promoted development of Type 2 diabetes. This is intended to provide improved insight into the pathogenesis of chronic circadian disorders that increase the risk of diabetes, and consider new targets for its metabolic and drug correction.

    Lay abstract

    Insulin resistance (IR) is a common adaptive mechanism, acting under opposite anabolic and catabolic conditions. However, chronic IR is a key pathological feature of obesity, Type 2 diabetes and cancer cachexia, whereas a temporal IR is widely seen in fasting, pregnancy, exercise and stress. Therefore, it is important to understand when this transient IR-mechanism shifts to chronic IR-associated diseases. What factors result in the switch between the anabolic and catabolic conditions and what defect(s) in this switch is associated with chronic IR induction? The present opinion article aimed to address these questions to the metabolic changes typical for circadian regulation in lean, obese and diabetic patients.

    Graphical abstract

    Early circadian IR disorders caused by overweight and obesity are associated with increased risk for diabetes via formation of a vicious cycle between lipid anabolic and catabolic programs thus distorting insulin and lipid levels in day/night period.

    References

    • 1 Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science 330, 1349–1354 (2010).
      Medline CASGoogle Scholar
    • 2 Shi S, Ansari T, McGulnness O et al. Circadian disruption leads to insulin resistance and obesity. Curr. Biol. 23, 372–381 (2013).
      Medline CASGoogle Scholar
    • 3 Wagner EF, Petrazzelli M. Cancer metabolism: a waste of insulin interference. Nature 521, 430–431 (2015).
      Medline CASGoogle Scholar
    • 4 Schwartsburd PM. Insulin resistance is a two-sided mechanism acting under opposite catabolic and anabolic conditions. Med. Hypothesis 89, 8–10 (2016).
      Medline CASGoogle Scholar
    • 5 Wei K, Piecewitcz SM, McGinnis LM et al. A liver HIF-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by VEGF inhibition. Nat. Med. 19, 1331–1337 (2013).
      Medline CASGoogle Scholar
    • 6 Saltiel A, Kahn R. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 41, 799–806 (2001).
      Google Scholar
    • 7 Kraegen E, Cooney G. Free fatty acids and skeletal muscle insulin resistance. Curr. Opin. Lipidol. 19, 235–241 (2008).
      Medline CASGoogle Scholar
    • 8 Jha PK, Challet E, Kalsbeek A. Circadian rhythms in glucose and lipid metabolism in nocturnal and diurnal mammals. Mol. Cell. Endocrinol. 418, 74–88 (2015).
      MedlineGoogle Scholar
    • 9 Shostak A, Husse J, Oster H. Circadian regulation of adipose function. Adipocyte 2, 201–206 (2013).
      Medline CASGoogle Scholar
    • 10 Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 339, 172–177 (2013).
      Medline CASGoogle Scholar
    • 11 Szutowicz A, Bielarczyk H, Jankowska-Kulawy A et al. Acetyl-CoA the key factor for survival or death of cholinergic neurons in course of neurodegenerative diseases. Neurochem. Res. 38, 1523–1542 (2013).
      Medline CASGoogle Scholar
    • 12 Adamovich Y, Aviram R, Asher G. The emerging roles of lipids in circadian control. Biochim. Biophys. Acta 1851, 1017–1025 (2015).
      Medline CASGoogle Scholar
    • 13 Morris C, Yang J, Garcia J et al. Endogenous circadian system and circadian misalignment impact glucose tolerance via separate mechanisms in human. Proc. Natl Acad. Sci. USA 112, E2225–E2234 (2015).
      Medline CASGoogle Scholar
    • 14 Carrasco-Benso M, Rivero-Gutierrez B, lopez-minguez J et al. Human adipose tissue express intrinsic circadian rhythm in insulin sensitivity. FASEB J. 30, 3117–3123 (2016).
      Medline CASGoogle Scholar
    • 15 Honma K, Hikosaka M, Mochizuki K, Goda T. Loss of circadian rhythm of circulating insulin concentration induced by high-fat diet intake is associated with disrupted rhythmic expression of circadian clock genes in the liver. Metabolism 65, 482–491 (2016).
      Medline CASGoogle Scholar
    • 16 Koska J, Ozias M, Deer J et al. A human model of dietary saturated fatty acid induced insulin resistance. Metabolism 65, 1621–1628 (2016).
      Medline CASGoogle Scholar
    • 17 Zhao W, Li A, Feng X et al. Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. Cell Signal. 28, 1401–1411 (2016).
      Medline CASGoogle Scholar
    • 18 Sun L, Wang Y, Song et al. Resveratrol restores the circadian rhythmic disorders of lipid metabolism induced by high-fat diet in mice. Biochem. Biophys. Res. Com. 458, 86–91 (2015).
      Medline CASGoogle Scholar
    • 19 Dilman VM. Development Aging And Disease: A New Rationale For An Intervention Strategy. Harwood Academic Publishing (1994).
      Google Scholar
    • 20 Hoehn K, Salmon A, Hohnen-Behrens C et al. Insulin resistance in a cellular antioxidant defense mechanism. Proc. Natl Acad. Sci. USA 106, 17787–17792 (2009).
      Medline CASGoogle Scholar
    • 21 Saltiel AR, Olefsky JM. Inflammatory mechanism linking obesity and metabolic disease. J. Clin. Invest. 127, 1–4 (2017).
      MedlineGoogle Scholar
    • 22 Ying W, Wollam J, Ofrecio JM et al. Adipose tissue B2 cells promote insulin resistance through leukotriene LTB4/LTD4R1 signaling. J. Clin. Invest. 127, 1019–1030 (2017).
      MedlineGoogle Scholar
    • 23 Uysal KT, Weisbrock SM, Marino MW, Hotamisigil GS. Protection from obesity-induced insulin resistance in mice lacking TNFα function. Nature 389, 610–614 (1997).
      Medline CASGoogle Scholar
    • 24 Stanley TL, Zanni MV, Johnsen S et al. TNF-α antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J. Clin. Endocrinol. Metabol. 96, E146–E150 (2011).
      Medline CASGoogle Scholar
    • 25 Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Invest. 126, 12–22 (2016).
      MedlineGoogle Scholar
    • 26 Landau BR, Wahren J, Chandramouli V et al. Contributions of gluconeogenesis to glucose production in the fasted state. J. Clin. Invest. 98, 378–385 (1996).
      Medline CASGoogle Scholar
    • 27 Rines AK, Sharabi K, Tavares CD, Puigserver P. Targeting hepatic glucose metabolism in the treatment of Type 2 diabetes. Nat. Rev. Drug Discov. 15, 786–804 (2016).
      Medline CASGoogle Scholar
    • 28 Koves TR, Ussher JR, Noland RC et al. Mitochondrial overload and incomplete fatty acis oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7, 45–56 (2008).
      Medline CASGoogle Scholar
    • 29 Hammarstedt A, Sopasakis VR, Gogg PA et al. Improved insulin sensitivity and adipose tissue desregulation after short-term treatment with pioglitazone in non-diabetic insulin resistance subject. Diabetologia 48, 96–104 (2005).
      Medline CASGoogle Scholar
    • 30 Ertunc ME, Hotamisligal GS. Lipid signaling and lipotoxicity in metabolic inflammation indications for metabolic disease pathogenesis and treatment. J. Lipid Res. 57(12), 2099–2114 (2016).
      Medline CASGoogle Scholar
    • 31 Girousse A, Tavernier G, Valle C et al. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. PLoS Biol. 11, e1001485 (2013).
      Medline CASGoogle Scholar
    • 32 Nielsen TS, Jessen N, Jorgensen JO et al. Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. J. Mol. Endocrinol. 52, R199–R222 (2014).
      Medline CASGoogle Scholar
    • 33 Zhang H, Hu J, Xu C et al. Mechanisms of metformin inhibiting lipolytic response to isoproterenol in primary rat adipocytes. J. Mol. Endocrinol. 42, 57–66 (2009).
      MedlineGoogle Scholar
    • 34 Ren T, He J, Jiang H et al. Metformin reduces lipolysis in primary rat adipocytes stimulated by TNF-α or isoproterenol. J. Mol. Endocrinol. 37, 175–183 (2006).
      Medline CASGoogle Scholar
    • 35 Foretz M, Hebrard S, Leclers J et al. Metformin inhibits hepatic gluconeogenesis in mice independly of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120, 2355–2369 (2009).
      Google Scholar
    • 36 Grober U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients 7, 8199–8226 (2015).
      MedlineGoogle Scholar
    • 37 Yuan X, Wei G, You Y et al. Rutin ameliorates obesity through brown fat activation. FASEB J. 31, 333–345 (2017).
      Medline CASGoogle Scholar
    • 38 Yuan M, Konstantopoulas N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293, 1673–1677 (2001).
      Medline CASGoogle Scholar
    • 39 Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agent aspirin and salicylate inhibit the activity of I(kappa)B-kinase-beta. Nature 396, 77–80 (1998).
      Medline CASGoogle Scholar
    • 40 Cooke A, Connaughton R, Lyons C et al. Fatty acids and chronic low grade inflammation associated with obesity and the metabolic syndrome. Eur. J. Pharmacol. 785, 207–214 (2016).
      Medline CASGoogle Scholar
    • 41 Connaughton R, McMorrow A, McGillicuddy A et al. Impact of anti-inflammatory nutrients on obesity-associated metabolic-inflammation from childhood through to adulthood. Proc. Nutr. Soc. 75, 115–124 (2016).
      MedlineGoogle Scholar
    • 42 Tuomi T, Nagorny C, Singh P et al. Increased melatonin signaling is a risk factor for Type 2 diabetes. Cell Metab. 23, 1067–1077 (2016).
      Medline CASGoogle Scholar
    • 43 Forrestel A, Miedlich S, Yurchesen M et al. Chronomedicine and type 2 diabetes: shining some light on melatonin. Diabetologia 10.1007/s00125-016-4175-1 (2016) (Epub ahead of print).
      MedlineGoogle Scholar
    • 44 Levit S, Giveon S, Philippov Y et al. Type 2 diabetes therapeutic strategies: why don't we see the «ELEPHANT» in the room? Diabetes Mellitus 19, 341–349 (2016).
      Google Scholar
    • 45 Nolan CJ, Ruderman NB, Kahn SE, Pedersen O, Prentki M. Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of Type 2 diabetes. Diabetes 64, 673–686 (2015).
      Medline CASGoogle Scholar
    • 46 Taegtmeyer H, Beauloye C, Harmancey R, Hue L. Insulin resistance protects the heart from fuel overload in dysregulated metabolic states. Am. J. Physiol. Heart Circ. Physiol. 305, H1693–H1697 (2013).
      Medline CASGoogle Scholar
    • 47 Fu Q, Xu B, Liu Y et al. Insulin inhibits cardiac contractility by inducing a Gi-biased adrenergic signaling in hearts. Diabetes 63, 2673–2689 (2014).
      Google Scholar
    • 48 Horita S, Seki G, Yamada H et al. Insulin resistance, obesity, hypertension, and renal sodium transport. Int. J. Hypertens. 2011, 391762 (2011).
      MedlineGoogle Scholar
    • 49 Ruderman NB, Shulman GI. The metabolic syndrome. In: Endocrinology: Adult and Pediatric, Volume I (6th Edition). De Groot LJ, Jamieson JI (Eds). Saunders, PA, USA, 828–839 (2010).
      Google Scholar
    • 50 Straub RH. Insulin resistance, selfish brain, and selfish immune system: an evolutionarily positively selected program used in chronic inflammatory diseases. Arthritis Res. Ther. 16(Suppl. 2), 54 (2014).
      Google Scholar
    • 51 Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and Type 2 diabetes. Nature 510, 82–91 (2014).
      Google Scholar
    • 52 Sylow L, Klenert M, Richter EA, Jensen TE. Exercise-stimulated glucose uptake – regulation and implications for glycaemic control. Nat. Rev. Endocrinol. 11, 133–148 (2017).
      Google Scholar
    • 53 Martel J, Ojcius DM, Chang CJ et al. Anti-obesogenic and antidiabetic effects of plants and mushrooms. Nat. Rev. Endocrinol. 13, 149–160 (2017).
      Medline CASGoogle Scholar
    • 54 Perry RJ, Peng L, Barry NA et al. Acetate mediate-brain-beta-cell axis to promote metabolic syndrome. Nature 534, 213–217 (2016).
      Medline CASGoogle Scholar